0 Σχόλια
0 Μοιράστηκε
109 Views
0 Προεπισκόπηση
Αναζήτηση
Ανακάλυψε νέους ανθρώπους, δημιούργησε νέες συνδέσεις και κάνε καινούργιους φίλους
-
Παρακαλούμε συνδέσου στην Κοινότητά μας για να δηλώσεις τι σου αρέσει, να σχολιάσεις και να μοιραστείς με τους φίλους σου!
-
Castleman Disease Treatment Market Regulatory Framework and Orphan Drug IncentivesThe regulatory landscape for Castleman disease treatment has evolved significantly to accommodate rare disease drug development, with specialized pathways and incentives that recognize the challenges of conducting traditional large-scale clinical trials in small patient populations. The U.S. Food and Drug Administration granted siltuximab orphan drug designation in 2007 and approved it for iMCD...0 Σχόλια 0 Μοιράστηκε 121 Views 0 Προεπισκόπηση
-
Castleman Disease Treatment Market Regulatory Framework and Orphan Drug IncentivesThe regulatory landscape for Castleman disease treatment has evolved significantly to accommodate rare disease drug development, with specialized pathways and incentives that recognize the challenges of conducting traditional large-scale clinical trials in small patient populations. The U.S. Food and Drug Administration granted siltuximab orphan drug designation in 2007 and approved it for iMCD...0 Σχόλια 0 Μοιράστηκε 103 Views 0 Προεπισκόπηση